ANI Pharmaceuticals, Inc.
Every calculator, already run for ANIP
Open the full toolkit →You have the numbers on ANIP. Get the argument.
A written report on which of these readings actually decide the outcome for ANI Pharmaceuticals, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
9 analysts covering ANIPAnalyst Price Target Disagreement for ANI Pharmaceuticals, Inc.
Wall Street's bull case implies +65% from the current price; the bear case implies +16%. A 49% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for ANIP
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baude…
ANIP — frequently asked
Is ANIP a buy right now?
Wall Street's consensus rating on ANI Pharmaceuticals, Inc. is Buy across 9 analysts, with a mean price target of $105.78 (+44% vs. the current $73.38). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is ANIP overvalued?
ANIP trades at 16.0x trailing earnings, against a DCF fair value of $224 per share. The current price implies -7% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is ANIP's next earnings date?
ANI Pharmaceuticals, Inc. is next scheduled to report earnings around Nov 6, 2026. A full ANIP research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for ANI Pharmaceuticals, Inc.?
Analysts covering ANI Pharmaceuticals, Inc. (ANIP) range from a bear-case target of $85.00 to a bull-case high of $121.00, with a mean consensus target of $105.78 across 9 analysts. The spread of $36.00 (49% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare ANI Pharmaceuticals, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For ANI Pharmaceuticals, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full ANIP research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on ANI Pharmaceuticals, Inc., in minutes. 3 free reports included with every account — no credit card required.